Cargando…
Impact of the Requirement of Bone Mineral Density Evidence on Utilization of Anti-osteoporosis Medications, Clinical Outcome and Medical Expenditures of Patient With Hip Fracture in Taiwan
Background: Since 2011, Taiwan’s National Health Insurance Administration (NHIA) issued a regulation on the reimbursement to anti-osteoporosis medications (AOMs). This study aimed to evaluate the impact of this regulation in reimbursement on the utilization of AOMs, clinical outcomes and associated...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Kerman University of Medical Sciences
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9309953/ https://www.ncbi.nlm.nih.gov/pubmed/33059424 http://dx.doi.org/10.34172/ijhpm.2020.169 |
_version_ | 1784753285862785024 |
---|---|
author | Wang, Chen-Yu Fu, Shau-Huai Hung, Chih-Chien Yang, Rong-Sen Lin, Jou-Wei Chen, Ho-Min Hsiao, Fei-Yuan Shen, Li-Jiuan |
author_facet | Wang, Chen-Yu Fu, Shau-Huai Hung, Chih-Chien Yang, Rong-Sen Lin, Jou-Wei Chen, Ho-Min Hsiao, Fei-Yuan Shen, Li-Jiuan |
author_sort | Wang, Chen-Yu |
collection | PubMed |
description | Background: Since 2011, Taiwan’s National Health Insurance Administration (NHIA) issued a regulation on the reimbursement to anti-osteoporosis medications (AOMs). This study aimed to evaluate the impact of this regulation in reimbursement on the utilization of AOMs, clinical outcomes and associated medical expenditures of patients with incident hip fractures. Methods: By using the National Health Insurance Research Database (NHIRD), patients with incident hip fracture from 2006 to 2015 were identified as our study cohort. Patients younger than 50 years old or prescribed with AOMs within one year prior to incident fracture were excluded. Outcomes of interest were quarterly estimates of the proportion of patients who received bone mineral density (BMD) examination, who were prescribed AOMs, as well as who encountered subsequent osteoporotic fracture-related visits and associated medical expenditures. Particularly, age- and gender specific estimates were reported. An interrupted time series study design with segmented regression model was used to quantitatively explore the impact of the changes of the reimbursement criteria on the level (immediate) and trend (long-term) changes of these outcomes. Results: Our study enrolled 118 493 patients with incident hip fracture with those patients aged older than 80 years old accounting for the largest proportion. A significantly decreased trend of AOMs prescription rates was observed immediately post regulation except for female aged between 65 and 80, while the long-term pattern showed no significant difference. However, the percentage of patients encountered subsequent osteoporotic fracture-related visit was not statistically different between pre- and post-regulation periods. Noteworthy, the policy regulation was associated with an increasing trend of osteoporotic fracture associated medical expenditures, especially for patients older than 80 years old. Conclusion: The regulation on the reimbursement for AOMs decreased the prescribing rate of AOMs immediately although the effect did not sustain thereafter. However, higher subsequent osteoporotic fracture-related medical expenditures were introduced, especially among those very old population. |
format | Online Article Text |
id | pubmed-9309953 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Kerman University of Medical Sciences |
record_format | MEDLINE/PubMed |
spelling | pubmed-93099532022-08-09 Impact of the Requirement of Bone Mineral Density Evidence on Utilization of Anti-osteoporosis Medications, Clinical Outcome and Medical Expenditures of Patient With Hip Fracture in Taiwan Wang, Chen-Yu Fu, Shau-Huai Hung, Chih-Chien Yang, Rong-Sen Lin, Jou-Wei Chen, Ho-Min Hsiao, Fei-Yuan Shen, Li-Jiuan Int J Health Policy Manag Original Article Background: Since 2011, Taiwan’s National Health Insurance Administration (NHIA) issued a regulation on the reimbursement to anti-osteoporosis medications (AOMs). This study aimed to evaluate the impact of this regulation in reimbursement on the utilization of AOMs, clinical outcomes and associated medical expenditures of patients with incident hip fractures. Methods: By using the National Health Insurance Research Database (NHIRD), patients with incident hip fracture from 2006 to 2015 were identified as our study cohort. Patients younger than 50 years old or prescribed with AOMs within one year prior to incident fracture were excluded. Outcomes of interest were quarterly estimates of the proportion of patients who received bone mineral density (BMD) examination, who were prescribed AOMs, as well as who encountered subsequent osteoporotic fracture-related visits and associated medical expenditures. Particularly, age- and gender specific estimates were reported. An interrupted time series study design with segmented regression model was used to quantitatively explore the impact of the changes of the reimbursement criteria on the level (immediate) and trend (long-term) changes of these outcomes. Results: Our study enrolled 118 493 patients with incident hip fracture with those patients aged older than 80 years old accounting for the largest proportion. A significantly decreased trend of AOMs prescription rates was observed immediately post regulation except for female aged between 65 and 80, while the long-term pattern showed no significant difference. However, the percentage of patients encountered subsequent osteoporotic fracture-related visit was not statistically different between pre- and post-regulation periods. Noteworthy, the policy regulation was associated with an increasing trend of osteoporotic fracture associated medical expenditures, especially for patients older than 80 years old. Conclusion: The regulation on the reimbursement for AOMs decreased the prescribing rate of AOMs immediately although the effect did not sustain thereafter. However, higher subsequent osteoporotic fracture-related medical expenditures were introduced, especially among those very old population. Kerman University of Medical Sciences 2020-10-03 /pmc/articles/PMC9309953/ /pubmed/33059424 http://dx.doi.org/10.34172/ijhpm.2020.169 Text en © 2022 The Author(s); Published by Kerman University of Medical Sciences https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0 (https://creativecommons.org/licenses/by/4.0/) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Article Wang, Chen-Yu Fu, Shau-Huai Hung, Chih-Chien Yang, Rong-Sen Lin, Jou-Wei Chen, Ho-Min Hsiao, Fei-Yuan Shen, Li-Jiuan Impact of the Requirement of Bone Mineral Density Evidence on Utilization of Anti-osteoporosis Medications, Clinical Outcome and Medical Expenditures of Patient With Hip Fracture in Taiwan |
title | Impact of the Requirement of Bone Mineral Density Evidence on Utilization of Anti-osteoporosis Medications, Clinical Outcome and Medical Expenditures of Patient With Hip Fracture in Taiwan |
title_full | Impact of the Requirement of Bone Mineral Density Evidence on Utilization of Anti-osteoporosis Medications, Clinical Outcome and Medical Expenditures of Patient With Hip Fracture in Taiwan |
title_fullStr | Impact of the Requirement of Bone Mineral Density Evidence on Utilization of Anti-osteoporosis Medications, Clinical Outcome and Medical Expenditures of Patient With Hip Fracture in Taiwan |
title_full_unstemmed | Impact of the Requirement of Bone Mineral Density Evidence on Utilization of Anti-osteoporosis Medications, Clinical Outcome and Medical Expenditures of Patient With Hip Fracture in Taiwan |
title_short | Impact of the Requirement of Bone Mineral Density Evidence on Utilization of Anti-osteoporosis Medications, Clinical Outcome and Medical Expenditures of Patient With Hip Fracture in Taiwan |
title_sort | impact of the requirement of bone mineral density evidence on utilization of anti-osteoporosis medications, clinical outcome and medical expenditures of patient with hip fracture in taiwan |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9309953/ https://www.ncbi.nlm.nih.gov/pubmed/33059424 http://dx.doi.org/10.34172/ijhpm.2020.169 |
work_keys_str_mv | AT wangchenyu impactoftherequirementofbonemineraldensityevidenceonutilizationofantiosteoporosismedicationsclinicaloutcomeandmedicalexpendituresofpatientwithhipfractureintaiwan AT fushauhuai impactoftherequirementofbonemineraldensityevidenceonutilizationofantiosteoporosismedicationsclinicaloutcomeandmedicalexpendituresofpatientwithhipfractureintaiwan AT hungchihchien impactoftherequirementofbonemineraldensityevidenceonutilizationofantiosteoporosismedicationsclinicaloutcomeandmedicalexpendituresofpatientwithhipfractureintaiwan AT yangrongsen impactoftherequirementofbonemineraldensityevidenceonutilizationofantiosteoporosismedicationsclinicaloutcomeandmedicalexpendituresofpatientwithhipfractureintaiwan AT linjouwei impactoftherequirementofbonemineraldensityevidenceonutilizationofantiosteoporosismedicationsclinicaloutcomeandmedicalexpendituresofpatientwithhipfractureintaiwan AT chenhomin impactoftherequirementofbonemineraldensityevidenceonutilizationofantiosteoporosismedicationsclinicaloutcomeandmedicalexpendituresofpatientwithhipfractureintaiwan AT hsiaofeiyuan impactoftherequirementofbonemineraldensityevidenceonutilizationofantiosteoporosismedicationsclinicaloutcomeandmedicalexpendituresofpatientwithhipfractureintaiwan AT shenlijiuan impactoftherequirementofbonemineraldensityevidenceonutilizationofantiosteoporosismedicationsclinicaloutcomeandmedicalexpendituresofpatientwithhipfractureintaiwan |